Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00712751 · ClinicalTrials.gov registry record
The Sexual Health of Rectal Cancer Patients
A clinical trial of Rectal Cancer and RECTUM, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 192
- Enrollment target
- 2
- Study locations
NCT00712751: Completed study of Rectal Cancer and RECTUM, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00712751 is a study of Rectal Cancer and RECTUM that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 192 participants, below the 3,164-participant average among 70 other Rectal Cancer trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00712751, a study of Rectal Cancer and RECTUM, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 192 participants
- Enrollment target
- 2
- Study locations
Study Summary
We know that treatment for rectal, colorectal or anal cancer can impact sexual function. This study aims to learn: * How the treatment affects emotional and social well-being. * How a new sexual health educational program affects you. Cancer patients seek education for lots of reasons. It often helps them cope because they can express their feelings with a trained professional. This study is open to individuals who have been treated for rectal, colorectal or anal cancer. It involves a new type of sexual health counseling program. It will teach participants skills that they can use to improve their sex lives. These skills may also improve physical and emotional well-being. We will compare the new type of sexual health program with the standard care patients receive after treatment for rectal, colorectal or anal cancer.
Primary Outcome
The FSFI (Female Sexual Functioning Index) is a brief, self-report measure of female sexual function. The 19 items use a 5-point Likert scale ranging from 1-5 with higher scores indicating greater levels of sexual function. The total score for the Female Sexual Function Index (FSFI) ranges from a minimum of 2.0 to a maximum of 36.0
Conditions Studied
Interventions
- BEHAVIORAL questionnaires
- BEHAVIORAL CSI-SH- Cancer Survivorship Intervention
Study Locations (2)
New York
- Mount Sinai Hospital - New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2008-06-24 |
| Est. Completion | 2024-11-21 |
What the finished NCT00712751 record still lists
NCT00712751 is an observational study that tracks outcomes without assigning an intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 3,164-participant average among 70 other Rectal Cancer trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Rectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which questionnaires is the first listed.
NCT00712751 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00712751 about?
NCT00712751 is a clinical study titled "The Sexual Health of Rectal Cancer Patients". We know that treatment for rectal, colorectal or anal cancer can impact sexual function. This study aims to learn: * How the treatment affects emotional and social well-being. * How a new sexual health educational program affects you. Cancer patients seek education for lots of reasons. It often he...
What is the current status of trial NCT00712751?
This trial is currently completed. The enrollment target is 192 participants. The study started on 2008-06-24. Estimated completion is 2024-11-21.
What conditions does trial NCT00712751 study?
This clinical trial studies the following conditions: Rectal Cancer, RECTUM.
What interventions are being tested in trial NCT00712751?
The interventions under investigation include: questionnaires (BEHAVIORAL), CSI-SH- Cancer Survivorship Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT00712751?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00712751 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00712751's enrollment target sits among peer trials
192 21st of 70 higher than 50 of 70 other Rectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
RECRUITING · Phase 1
-
Exosomes in Rectal Cancer
RECRUITING
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
RECRUITING · Phase 2
-
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
RECRUITING · NA
-
Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy